ClinicalTrials.gov
ClinicalTrials.gov Menu

Alternate-Day Buprenorphine Administration. Phase II - 4

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00000222
Recruitment Status : Completed
First Posted : September 21, 1999
Last Update Posted : June 24, 2005
Sponsor:
Collaborator:
University of Vermont
Information provided by:
National Institute on Drug Abuse (NIDA)

September 20, 1999
September 21, 1999
June 24, 2005
July 1992
Not Provided
  • Drug use
  • Opioid withdrawal
  • Opioid agonist effects
  • Dose identification
  • Pupil diameter
Same as current
No Changes Posted
Not Provided
Not Provided
Not Provided
Not Provided
 
Alternate-Day Buprenorphine Administration. Phase II - 4
Alternate-Day Buprenorphine Administration. Phase II
The purpose of this study is to determine if two times a subject's daily maintenance dose will hold for 48 hours without changes in agonist and antagonist effects.
Not Provided
Interventional
Phase 1
Intervention Model: Crossover Assignment
Primary Purpose: Treatment
Opioid-Related Disorders
Drug: Buprenorphine
Not Provided
Amass, bickel, Crean, Blake, Higgins (in press). Alternate day buprenorphine dosing as efficacious and preferred to daily dosing in opioid dependent humans. Psychopharmacology. Amass, Bickel, Crean, Blake, Higgins. (in press) Alternate day buprenorphine dosing as efficacious and preferred to daily dosing in opioid dependent humans. Psychopharmacology

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
0
Same as current
Not Provided
Not Provided
Please contact site for information.
Sexes Eligible for Study: All
28 Years to 45 Years   (Adult)
No
Contact information is only displayed when the study is recruiting subjects
United States
 
 
NCT00000222
NIDA-06969-4
R01-06969-4
Not Provided
Not Provided
Not Provided
Not Provided
National Institute on Drug Abuse (NIDA)
University of Vermont
Principal Investigator: Warren Bickel, Ph.D. University of Vermont
National Institute on Drug Abuse (NIDA)
December 1993

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP